Antineoplastic

Antineoplastics
Tabine series
2-Deoxy-D-ribose [intermediate]
2-Fluoroadenosine [HOT] [intermediate]
Zomib series
(R)-BoroLeu-(+)-Pinanediol-CF3COOH [HOT] [intermediate]

 

 

 

Antineoplastic Antibiotics
336.2g Streptozocin,>99%;75g Adriamycin HCl,USP37;52g Mitomycin C,USP35; 20g Actinomycin D are in-stock
18883-66-4
>99%
Streptozocin [HOT]
Appearance
Pale yellow crystalline powder
Solubility
Soluble in water
UV Absorption
The UV absorption of 0.001% solution
in water exhibits a maximum at about
228nm
Element Analysis
Carbon, Nitrogen, Hydrogen
Melting point
121°C(DEC)
[α]D(c=1,H2O)
+39°
α Isomer%
≥75%
Assay
99%
 
25316-40-9
USP35
50-07-7
USP35
50-76-0
11056-06-7
Tabine series
650g Decitabine,99%;1.2kg 2-Fluoroadenosine,>99% are in-stock
2353-33-5
>99%
2-Deoxy-D-ribose [intermediate]
533-67-5
Decitabine intermediate
75607-67-9
>99%
2-Fluoroadenosine [HOT] [intermediate]
146-78-1
Fludarabine intermediate
Zomib series
2.6kg (R)-BoroLeu-(+)-Pinanediol-CF3COOH,>97% is in-stock
179324-69-7
>99%
(R)-BoroLeu-(+)-Pinanediol-CF3COOH [HOT] [intermediate]
179324-87-9
Bortezomib intermediate
Patent Disclaimer
PD1
Products protected by valid patents are not offered for sale in jurisdictions where the sale of such products constitutes a patent infringement. The current list only reflects the products and technologies that are available, under development: note that some products may be developed or produced for internal and experimental uses with no commercal aim.
PD2
Sales of products are limited to those allowed by Chapter VII PLPRC 63, the above includes Research and development quantities.
PD3
the buyer assumes responsibility of all patent considerations in the use of
Lano ’s Pharmaceutical Co.,Ltd product(s).
PD4
R&D use in accordance with (1) 35 USC 271(e)+A13(1) in the U.S.; (2) Section 69.1 of Japanese Patent Law in Japan; (3) Section 11, No. 2 of the German Patent Act of 1981 in Germany; (iv) Section 60, Paragraph 5b of the U.K. Patents Act of 1977 in the U.K.; (4) Sections 55.2(1) and 55.2(6) and other common law exemptions of Canadian patent law; (5) Section 68B of the Patents Act of 1953 in New Zealand together with the amendment of same by the Statutes Amendment Bill of 2002; (6) such related legislation and/or case law as may be or become applicable in the aforementioned countries; and (7) such similar laws and rules as may apply in various other countries.